Sanuwave's 3% Q2 Sales Drop Masks a 40–60 Lost-Systems Problem

Revenue missed, but the usage data pointed to a system-placement squeeze

At first glance, Sanuwave's second quarter looked weak. The company reported $9.74 million in revenue versus $11.5 million expected. But the operating data suggested the problem was concentrated in new equipment placements rather than in day-to-day product usage.

Management said used equipment likely displaced 40 to 60 new system sales in the quarter. That is primarily an equipment-cycle issue. If UltraMIST were losing clinical traction, the weaker signal would likely show up more broadly.

It did not. Sanuwave still posted an all-time record for UltraMist applicator unit volumes. That suggests clinicians were still using the systems and consuming supplies at a strong pace.

So the key question for the next report is whether this was a temporary pressure point in new system sales or the start of a broader earnings slowdown. The evidence so far points more toward the former, but guidance has now been withdrawn, which keeps the risk alive.

UltraMIST usage held up even as the quarter's economics weakened

Applicator demand still looks healthy

On usage, UltraMIST still looks functional. Applicator revenue increased 13% to $7.3 million, after consumables utilization increased 22% year over year and 4% sequentially. The installed base also kept growing, with active systems increased to 1,411 from 1,382 in the first quarter.

That does not prove the quarter was healthy overall. It does suggest the product is still seeing repeat use in practice rather than sitting unused.

System sales and margin pressure tell a tougher story

The weaker side of the quarter was just as clear. Sanuwave sold 82 UltraMIST systems in Q2, down from 116 a year earlier, and management said UltraMIST system revenue fell 34%. That matters because system placements feed both current revenue and the installed base that drives recurring demand.

Profitability also softened. Gross margin fell to 76.2% from 78.1% a year earlier. In plain terms, the business was generating less profit from each dollar of sales even as the consumable side kept growing.

The market is now weighing product demand against earnings quality

The bull case is straightforward: the core product still appears to have real-world utility, and the installed base is still expanding. The bear case is that revenue, operating results, and adjusted EBITDA all weakened, while expenses rose. A product can be useful and still produce a messy earnings picture.

That is why the next update matters. The company has already flagged proposed Medicare reimbursement changes, and CMS's draft stance is mixed: physician-office UltraMIST reimbursement could fall from roughly $397 to $316, while hospital outpatient reimbursement could rise 14%. That makes site mix and reimbursement exposure more important than simple usage trends.

What to watch in the Q3 report

A healthier setup would include some combination of these signals:

• clearer commentary that hospital outpatient reimbursement could rise 14%, suggesting site mix may help offset physician-office pressure
• improved system-placement commentary after the 40 to 60 new system sales headwind
• continued consumable strength, consistent with prior applicator revenue increased 13% growth

A weaker setup would look like this:

• system sales remain as soft as Q2, with no sign of recovery
• margin pressure persists
• management cannot show that the uncertainty behind the withdrawn guidance is easing

For now, the cleanest read is simple: Sanuwave's quarter looked worse on revenue than it did on usage. Whether that distinction matters for the stock will depend on whether new system sales stabilize and whether reimbursement changes begin to affect demand.